DiabetOmics Laboratories

DiabetOmics (now operating as Modality Dx) is a medical diagnostics company specializing in non-invasive, point-of-care (POC) testing for diabetes, maternal health, and autoimmune diseases. Founded in 2008 and headquartered in Hillsboro, Oregon, the company utilizes proprietary molecular signature technology and oral fluid platforms to provide rapid risk assessment and disease monitoring. Its flagship product, the Lumella Preeclampsia Test, measures glycosylated fibronectin to identify expectant mothers at risk of preeclampsia. The company also develops saliva-based tests for diabetes (Glucema and Insudex) and rheumatoid arthritis (RAprime). With manufacturing facilities in India and a focus on global health, DiabetOmics aims to improve patient outcomes through early detection and personalized health management.